Every 10-Q that Edgewise Therapeutics, Inc. (EWTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EWTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EWTX filings page.
Edgewise Therapeutics, Inc. reported a net loss of $57.3 million for the three months and $106.3 million for the six months ended June 30, 2026, wider than a year earlier as it increased investment in its pipeline. Research and development expenses rose to $47.5 million in the quarter, driven by EDG-7500 and EDG-15400 clinical activities and higher personnel costs, while general and administrative expenses grew to $14.4 million on commercial readiness and transaction-related spending.
As of June 30, 2026, Edgewise held $460.7 million in cash, cash equivalents and marketable securities. On July 10, 2026 it closed the Sevasemten Sale to Servier, receiving $1,550 million in upfront cash and eligibility for up to $1,100 million in additional milestones, for aggregate potential consideration of $2,650 million. Management states that existing cash plus the upfront proceeds are expected to fund operations for at least 12 months while advancing lead cardiovascular programs EDG-7500 and EDG-15400.
Edgewise Therapeutics reported a net loss of $49.0 million for the three months ended March 31, 2026, as it continued investing heavily in late-stage clinical programs for severe muscle and cardiac diseases. Research and development expenses rose to $42.7 million, with spending focused on sevasemten, EDG-7500, EDG-15400 and discovery work.
The company held $499.6 million in cash, cash equivalents and marketable securities as of March 31, 2026 and believes this will fund operations for at least 12 months. Total assets were $518.5 million and stockholders’ equity was $493.2 million, reflecting a development-stage profile with an accumulated deficit of $595.4 million and no product revenue yet.
Edgewise Therapeutics (EWTX) filed its Q3 2025 10-Q, reporting a net loss of $40.7 million on operating expenses of $46.9 million. Research and development was $37.5 million and general and administrative was $9.4 million. Interest income contributed $6.2 million.
Liquidity remained strong with cash, cash equivalents and marketable securities of $563.3 million as of September 30, 2025, supported by an April 2025 underwritten registered direct offering of 9,935,419 shares at $20.13 per share for $200.0 million gross ($187.1 million net). For the first nine months, net cash used in operations was $105.2 million, reflecting continued investment in pipeline programs.
The company advanced multiple clinical assets: sevasemten in Phase 2 trials for Becker and Duchenne muscular dystrophy (including a pivotal cohort in Becker), EDG‑7500 in a multipart Phase 2 for hypertrophic cardiomyopathy, and EDG‑15400 in a Phase 1 study. Shares outstanding were 105,761,949 as of September 30, 2025, and 105,868,434 as of October 31, 2025. Management believes current liquidity will fund operations for at least the next 12 months.